Open an account

Denali Therapeutics

DNLI · NASDAQ

$18.93+$0.89 (+4.93%)TodayMarket closed ·
Prev close $18.04

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The company is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. The company is also pursuing opportunities in other disease areas including oncology.

Employees
503
Headquarters
South San Francisco, California
Listed
Dec 8, 2017
Sector
Health Care
Industry
Biotechnology
Website
denalitherapeutics.com

DNLI key statistics

Market cap
3.03B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.01M
Volume
1.82M
Open price
$18.10
High today
$19.35
Low today
$17.95
52 Week high
$27.30
52 Week low
$13.75

Denali Therapeutics (DNLI) at a glance

Denali Therapeutics (DNLI) last traded at $18.93, with a market cap of 3.03B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.95 and $19.35. The current price is 5.5% above the day's low and 2.2% below its high.

Volume so far is 1.82M shares, in line with the average of 2.01M shares a day.

Over the past year Denali Therapeutics has ranged from $13.75 to $27.30, and now sits 38% of the way up that range.

Denali Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.68 per share against an estimate of -$0.6699.

The average analyst price target is $37.26, 96.9% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 13 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 18 analystsAvg $37.26
Low
$27.27
Now
$18.93
High
$44.10

DNLI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 6.9% on average.

  1. Q3 FY24: reported -$0.63 per share against an estimate of -$0.6269
  2. Q4 FY24: reported -$0.67 per share against an estimate of -$0.8195
  3. Q1 FY25: reported -$0.78 per share against an estimate of -$0.70
  4. Q2 FY25: reported -$0.72 per share against an estimate of -$0.7338
  5. Q3 FY25: reported -$0.74 per share against an estimate of -$0.7669
  6. Q4 FY25: reported -$0.73 per share against an estimate of -$0.759
  7. Q1 FY26: reported -$0.69 per share against an estimate of -$0.7405
  8. Q2 FY26: reported -$0.68 per share against an estimate of -$0.6699

DNLI news

  • Ananya Gairola

    Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'

  • Press releaseGlobe Newswire

    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

  • Vandana Singh

    Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

  • Press releasePRNewswire

    The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

  • Vandana Singh

    FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease

  • FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome

  • Press releasePRNewswire

    Advanced Cell-based Therapy Booming the Success for Healthcare Sector

  • Press releaseGlobe Newswire

    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

Similar companies

Companies in the same industry as Denali Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.